VV169 for Multiple Myeloma

This trial tests a new treatment called VV169, which uses modified T-cells (a type of immune cell) to target multiple myeloma, a type of blood cancer. The goal is to determine the treatment's safety and understand its effects on patients whose cancer has returned or doesn't respond to standard treatments. The trial welcomes individuals who have undergone multiple myeloma treatments, particularly those whose cancer persists or recurs despite usual treatments. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative therapy.

The trial information does not specify if you need to stop taking your current medications. However, if you are on HIV antiretroviral therapy, it may interfere with the trial treatment.

Research has shown that VV169, a new treatment for multiple myeloma, holds promise in early studies. In tests with mice, VV169 completely eliminated myeloma tumors within 28 days. While encouraging, results in animals don't always translate to humans.

In human studies, the treatment has generally been safe. Common side effects include infections, a decrease in blood cells, and mild to moderate cytokine release syndrome (CRS), an immune reaction. Although there are some risks, early testing has found the side effects manageable.

Researchers are excited about VV169 for multiple myeloma because it offers a fresh approach to treating this cancer. Unlike standard treatments like proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, VV169 is exploring new dosing strategies with its dose escalation and expansion phases. This could potentially lead to more personalized treatment plans, enhancing effectiveness while minimizing side effects. The innovative strategy behind VV169 may provide renewed hope for patients, especially those who have not responded to previous treatments.

Research has shown that VV169, a type of CAR T-cell therapy, could be promising for treating multiple myeloma. In a study with mice, researchers completely cleared myeloma tumors within 28 days after administering VV169. This outcome suggests that the treatment might also work well in humans. CAR T-cell therapies involve modifying a patient's T-cells (a type of immune cell) to help them attack cancer cells more effectively. Although human studies provide limited information, these early results offer hope for people with multiple myeloma that has returned or is not responding to other treatments. Participants in this trial will receive VV169, with some in the dose escalation phase for those with prior lines of treatment and others in the dose expansion phase for those with no prior lines of treatment.³⁵⁶⁷⁸